APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Human Rotavirus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Rotavirus Vaccine Market Outlook and Growth Opportunities 2026

Report ID 174000100420 December 2025198 pages

Choose your research edition.

Industry ResearchHuman Rotavirus Vaccine Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Rotavirus Vaccine Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Human Rotavirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Rotavirus Vaccine Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Rotavirus Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Human Rotavirus Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Rotavirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Rotavirus Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Rotavirus Vaccine market include Bharat Biotech, GlaxoSmithKline and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Rotavirus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Rotavirus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Rotavirus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Rotavirus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Rotavirus Vaccine Segment by Company

Bharat Biotech

GlaxoSmithKline

Merck

Human Rotavirus Vaccine Segment by Type

Rotarix

RotaTeq

Lanzhou lamb

Rotavin-M1

Rotavac

Others

Human Rotavirus Vaccine Segment by Application

Hospitals & Clinics

Academic And Research

Others

Human Rotavirus Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Rotavirus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Rotavirus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Rotavirus Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Human Rotavirus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rotavirus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Rotavirus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Rotavirus Vaccine industry.

Chapter 3: Detailed analysis of Human Rotavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Rotavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Rotavirus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Rotavirus Vaccine Industry Trends Table 2. Human Rotavirus Vaccine Industry Drivers Table 3. Human Rotavirus Vaccine Industry Opportunities and Challenges Table 4. Human Rotavirus Vaccine Industry Restraints Table 5. Global Human Rotavirus Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Rotavirus Vaccine Revenue Share by Company (2021-2026) Table 7. Global Human Rotavirus Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Rotavirus Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Human Rotavirus Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Human Rotavirus Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Rotavirus Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Human Rotavirus Vaccine Company, Product Type & Application Table 13. Global Human Rotavirus Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Rotavirus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rotarix Table 18. Significant Companies of RotaTeq Table 19. Significant Companies of Lanzhou lamb Table 20. Significant Companies of Rotavin-M1 Table 21. Significant Companies of Rotavac Table 22. Significant Companies of Others Table 23. Global Human Rotavirus Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Human Rotavirus Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Human Rotavirus Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Human Rotavirus Vaccine Sales Volume Share by Type (2021-2026) Table 27. Global Human Rotavirus Vaccine Sales Volume Share by Type (2027-2032) Table 28. Global Human Rotavirus Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Human Rotavirus Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Human Rotavirus Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Human Rotavirus Vaccine Sales Value Share by Type (2021-2026) Table 32. Global Human Rotavirus Vaccine Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospitals & Clinics Table 34. Significant Companies of Academic And Research Table 35. Significant Companies of Others Table 36. Global Human Rotavirus Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Human Rotavirus Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 38. Global Human Rotavirus Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 39. Global Human Rotavirus Vaccine Sales Volume Share by Application (2021-2026) Table 40. Global Human Rotavirus Vaccine Sales Volume Share by Application (2027-2032) Table 41. Global Human Rotavirus Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Human Rotavirus Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Human Rotavirus Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Human Rotavirus Vaccine Sales Value Share by Application (2021-2026) Table 45. Global Human Rotavirus Vaccine Sales Value Share by Application (2027-2032) Table 46. Global Human Rotavirus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 47. Global Human Rotavirus Vaccine Sales by Region (2021-2026) & (K Units) Table 48. Global Human Rotavirus Vaccine Sales Market Share by Region (2021-2026) Table 49. Global Human Rotavirus Vaccine Sales by Region (2027-2032) & (K Units) Table 50. Global Human Rotavirus Vaccine Sales Market Share by Region (2027-2032) Table 51. Global Human Rotavirus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Human Rotavirus Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Human Rotavirus Vaccine Sales Value Share by Region (2021-2026) Table 54. Global Human Rotavirus Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Human Rotavirus Vaccine Sales Value Share by Region (2027-2032) Table 56. Global Human Rotavirus Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Human Rotavirus Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Human Rotavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Global Human Rotavirus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Human Rotavirus Vaccine Sales by Country (2021-2026) & (K Units) Table 61. Global Human Rotavirus Vaccine Sales Market Share by Country (2021-2026) Table 62. Global Human Rotavirus Vaccine Sales by Country (2027-2032) & (K Units) Table 63. Global Human Rotavirus Vaccine Sales Market Share by Country (2027-2032) Table 64. Global Human Rotavirus Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Human Rotavirus Vaccine Sales Value Market Share by Country (2021-2026) Table 66. Global Human Rotavirus Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Human Rotavirus Vaccine Sales Value Market Share by Country (2027-2032) Table 68. Bharat Biotech Company Information Table 69. Bharat Biotech Business Overview Table 70. Bharat Biotech Human Rotavirus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bharat Biotech Human Rotavirus Vaccine Product Portfolio Table 72. Bharat Biotech Recent Development Table 73. GlaxoSmithKline Company Information Table 74. GlaxoSmithKline Business Overview Table 75. GlaxoSmithKline Human Rotavirus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Human Rotavirus Vaccine Product Portfolio Table 77. GlaxoSmithKline Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck Human Rotavirus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Merck Human Rotavirus Vaccine Product Portfolio Table 82. Merck Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Human Rotavirus Vaccine Distributors List Table 86. Human Rotavirus Vaccine Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Human Rotavirus Vaccine Product Image Figure 2. Global Human Rotavirus Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Rotavirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Rotavirus Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Human Rotavirus Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Human Rotavirus Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rotarix Image Figure 10. RotaTeq Image Figure 11. Lanzhou lamb Image Figure 12. Rotavin-M1 Image Figure 13. Rotavac Image Figure 14. Others Image Figure 15. Global Human Rotavirus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Human Rotavirus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Human Rotavirus Vaccine Sales Volume Share by Type (2021-2032) Figure 18. Global Human Rotavirus Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Human Rotavirus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Human Rotavirus Vaccine Sales Value Share by Type (2021-2032) Figure 21. Hospitals & Clinics Image Figure 22. Academic And Research Image Figure 23. Others Image Figure 24. Global Human Rotavirus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Human Rotavirus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Human Rotavirus Vaccine Sales Volume Share by Application (2021-2032) Figure 27. Global Human Rotavirus Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Human Rotavirus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Human Rotavirus Vaccine Sales Value Share by Application (2021-2032) Figure 30. Global Human Rotavirus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 31. Global Human Rotavirus Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Human Rotavirus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Human Rotavirus Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Human Rotavirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. North America Human Rotavirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Human Rotavirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Human Rotavirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Human Rotavirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Human Rotavirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Human Rotavirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. South America Human Rotavirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Human Rotavirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Human Rotavirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Human Rotavirus Vaccine Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Human Rotavirus Vaccine Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Rotarix
  • RotaTeq
  • Lanzhou lamb
  • Rotavin-M1
  • Rotavac
  • Others
Applications
  • Hospitals & Clinics
  • Academic And Research
  • Others
Companies covered
  • Bharat Biotech
  • GlaxoSmithKline
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Rotavirus Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Human Rotavirus Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Human Rotavirus Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Rotavirus Vaccine Market Dynamics
  1. 2.1 Human Rotavirus Vaccine Industry Trends
  2. 2.2 Human Rotavirus Vaccine Industry Drivers
  3. 2.3 Human Rotavirus Vaccine Industry Opportunities and Challenges
  4. 2.4 Human Rotavirus Vaccine Industry Restraints
3 Human Rotavirus Vaccine Market by Company
  1. 3.1 Global Human Rotavirus Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Human Rotavirus Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Human Rotavirus Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Rotavirus Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Human Rotavirus Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Human Rotavirus Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Rotavirus Vaccine Company Product Type and Application
  8. 3.8 Global Human Rotavirus Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Rotavirus Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Rotavirus Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Rotavirus Vaccine Market by Type
  1. 4.1 Human Rotavirus Vaccine Type Introduction
  2. 4.1.1 Rotarix
  3. 4.1.2 RotaTeq
  4. 4.1.3 Lanzhou lamb
  5. 4.1.4 Rotavin-M1
  6. 4.1.5 Rotavac
  7. 4.1.6 Others
  8. 4.2 Global Human Rotavirus Vaccine Sales Volume by Type
  9. 4.2.1 Global Human Rotavirus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Human Rotavirus Vaccine Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Human Rotavirus Vaccine Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Human Rotavirus Vaccine Sales Value by Type
  13. 4.3.1 Global Human Rotavirus Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Human Rotavirus Vaccine Sales Value by Type (2021-2032)
  15. 4.3.3 Global Human Rotavirus Vaccine Sales Value Share by Type (2021-2032)
5 Human Rotavirus Vaccine Market by Application
  1. 5.1 Human Rotavirus Vaccine Application Introduction
  2. 5.1.1 Hospitals & Clinics
  3. 5.1.2 Academic And Research
  4. 5.1.3 Others
  5. 5.2 Global Human Rotavirus Vaccine Sales Volume by Application
  6. 5.2.1 Global Human Rotavirus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Rotavirus Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Human Rotavirus Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Human Rotavirus Vaccine Sales Value by Application
  10. 5.3.1 Global Human Rotavirus Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Rotavirus Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Human Rotavirus Vaccine Sales Value Share by Application (2021-2032)
6 Human Rotavirus Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Human Rotavirus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Rotavirus Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Human Rotavirus Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Human Rotavirus Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Human Rotavirus Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Rotavirus Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Rotavirus Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Rotavirus Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Human Rotavirus Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Rotavirus Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Human Rotavirus Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Rotavirus Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Human Rotavirus Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Rotavirus Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Rotavirus Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Rotavirus Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Human Rotavirus Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Rotavirus Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Rotavirus Vaccine Sales Value Share by Country, 2025 VS 2032
7 Human Rotavirus Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Human Rotavirus Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Rotavirus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Rotavirus Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Human Rotavirus Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Human Rotavirus Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Human Rotavirus Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Rotavirus Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Rotavirus Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Rotavirus Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Rotavirus Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Rotavirus Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bharat Biotech
  2. 8.1.1 Bharat Biotech Company Information
  3. 8.1.2 Bharat Biotech Business Overview
  4. 8.1.3 Bharat Biotech Human Rotavirus Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bharat Biotech Human Rotavirus Vaccine Product Portfolio
  6. 8.1.5 Bharat Biotech Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Human Rotavirus Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Human Rotavirus Vaccine Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Human Rotavirus Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Human Rotavirus Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Rotavirus Vaccine Value Chain Analysis
  2. 9.1.1 Human Rotavirus Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Rotavirus Vaccine Sales Mode & Process
  6. 9.2 Human Rotavirus Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Rotavirus Vaccine Distributors
  9. 9.2.3 Human Rotavirus Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst